Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY044
MIFTS: 60

Larynx Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Larynx Cancer

About this section

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer 12 15
Laryngeal Carcinoma 12 77 54 30 56 15
Laryngeal Cancer 54 38 56
Carcinoma of Larynx 12 74
Laryngeal Neoplasm 17 74
Malignant Neoplasm of Larynx 74
Laryngeal Neoplasms 45
Cancer, Laryngeal 41
Cancer of Larynx 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:2596 DOID:2600
KEGG 38 H00055
ICD9CM 36 161 161.9
MeSH 45 D007822
NCIt 51 C4855 C7484
SNOMED-CT 69 93859007
ICD10 34 C32 C32.9
Sources

Summaries for Larynx Cancer

About this section
Disease Ontology : 12 A larynx cancer that has material basis in epithelial cells.

MalaCards based summary : Larynx Cancer, also known as laryngeal carcinoma, is related to laryngeal squamous cell carcinoma and verrucous carcinoma. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Magnesium Sulfate and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and lymph node, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Wikipedia : 77 Laryngeal cancer are mostly squamous cell carcinomas, reflecting their origin from the skin of the... more...

Sources

Related Diseases for Larynx Cancer

About this section

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 laryngeal squamous cell carcinoma 31.1 CCND1 CDKN2A EGFR GSTM3 GSTT1 MIR21
2 verrucous carcinoma 30.4 CCND1 CDKN2A TP53
3 in situ carcinoma 30.1 CDKN2A EGFR TP53
4 asbestosis 30.1 GSTM1 GSTP1 GSTT1
5 small cell carcinoma 30.1 CDKN2A EGFR TP53
6 malignant peritoneal mesothelioma 29.9 CDKN2A EGFR
7 inverted papilloma 29.9 CCND1 CDKN2A TP53
8 basaloid squamous cell carcinoma 29.8 CDKN2A EGFR TP53
9 oropharynx cancer 29.8 CCND1 CDKN2A EGFR TP53
10 recurrent respiratory papillomatosis 29.7 EGFR TP53
11 adenocarcinoma 29.6 CCND1 CDKN2A EGFR TP53
12 lynch syndrome 29.4 CCND1 CDKN2A EGFR GSTM1 TP53
13 thyroid cancer 28.8 CCND1 EGFR GSTT1 SERPINB5 TERT TP53
14 nasopharyngeal carcinoma 28.6 CCND1 CDKN2A EGFR GSTM1 NME1 TERT
15 squamous cell carcinoma 28.6 CCND1 CD44 CDKN2A EGFR GSTP1 MMP2
16 pancreatic cancer 28.6 CCND1 CD44 CDKN2A DLEU2 EGFR MIR21
17 squamous cell carcinoma, head and neck 27.9 CCND1 CD44 CDKN2A EGFR FAM3D-AS1 GSTM1
18 esophageal cancer 27.8 CCND1 CD44 CDKN2A EGFR GSTM1 GSTP1
19 cervical cancer 27.8 CCND1 CD44 CDKN2A GSTM1 GSTP1 GSTT1
20 ovarian cancer 27.7 CCND1 CD44 EGFR GSTP1 MIR21 MMP2
21 lung cancer 27.5 CCND1 CD44 CDKN2A EGFR GSTM1 GSTP1
22 breast cancer 27.4 CCND1 CD44 CTSD EGFR GSTP1 MIR21
23 laryngeal cancer, childhood 12.1
24 supraglottic laryngeal cancer 11.5
25 laryngeal mucoepidermoid carcinoma 11.1
26 laryngeal adenoid cystic carcinoma 11.1
27 laryngeal small cell carcinoma 11.1
28 larynx sarcoma 11.0
29 hearing loss, noise-induced 10.4 GSTM1 GSTT1
30 sister chromatid exchange, frequency of 10.4 GSTM1 GSTT1 XRCC1
31 drug-induced hepatitis 10.4 GSTM1 GSTT1 NAT2
32 breast papillomatosis 10.4 CCND1 CDKN2A
33 diffuse gastric cancer 10.4 GSTM1 GSTP1 GSTT1
34 senile cataract 10.4 GSTM1 GSTT1 XRCC1
35 tonsil squamous cell carcinoma 10.3 CCND1 CDKN2A
36 bladder squamous cell carcinoma 10.3 CDKN2A TP53
37 gastric adenosquamous carcinoma 10.3 CD44 CDKN2A TP53
38 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
39 xeroderma pigmentosum, complementation group d 10.3 GSTM1 GSTP1 GSTT1 XRCC1
40 male reproductive system disease 10.3 CCND1 GSTP1 TP53
41 brain ependymoma 10.2 EGFR TP53
42 skin carcinoma in situ 10.2 CCND1 CDKN2A
43 acute lymphocytic leukemia 10.2 CDKN2A GSTM1 GSTT1 TP53
44 spitz nevus 10.2 CDKN2A TP53
45 fibrosclerosis of breast 10.2 ENG XRCC1
46 nasopharyngeal disease 10.2 CCND1 CDKN2A TP53
47 retinal cancer 10.2 CCND1 CDKN2A TP53
48 bowenoid papulosis 10.2 CCND1 CDKN2A TERT
49 cervix disease 10.2 CCND1 CDKN2A TP53
50 basal cell carcinoma 10.2 GSTM1 GSTM3 GSTT1 TP53

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):


Bronchitis Deficiency Anemia
Pharynx Cancer Protein-Energy Malnutrition
Respiratory Failure Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:



Diseases related to Larynx Cancer
Sources

Symptoms & Phenotypes for Larynx Cancer

About this section

GenomeRNAi Phenotypes related to Larynx Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCND1 CD44 EGFR GSTM1 GSTM3 MMP2

MGI Mouse Phenotypes related to Larynx Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.21 CCND1 CD44 CDKN2A CTSD EGFR ENG
2 hematopoietic system MP:0005397 10.1 CCND1 CD44 CDKN2A CTSD EGFR ENG
3 mortality/aging MP:0010768 10.1 CCND1 CD44 CDKN2A CTSD EGFR ENG
4 digestive/alimentary MP:0005381 10.06 CCND1 CD44 CDKN2A CTSD EGFR ENG
5 integument MP:0010771 9.97 CCND1 CD44 CDKN2A CTSD EGFR ENG
6 neoplasm MP:0002006 9.91 CCND1 CD44 CDKN2A EGFR MMP2 NME1
7 nervous system MP:0003631 9.9 CCND1 CD44 CDKN2A CTSD EGFR ENG
8 normal MP:0002873 9.61 CCND1 CD44 EGFR ENG MMP2 SERPINB5
9 respiratory system MP:0005388 9.23 CCND1 CD44 CDKN2A EGFR ENG MMP2
Sources

Drugs & Therapeutics for Larynx Cancer

About this section

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
2
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
3
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
4
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
5
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2 7440-70-2 271
6 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anesthetics Phase 4,Phase 3,Not Applicable
9 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10 Pharmaceutical Solutions Phase 4,Phase 1,Early Phase 1,Not Applicable
11 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Tocolytic Agents Phase 4
16 Anti-Arrhythmia Agents Phase 4
17 Hormones Phase 4,Phase 2,Phase 3,Phase 1
18 calcium channel blockers Phase 4
19 Calcium, Dietary Phase 4,Phase 3,Phase 2
20 Anticonvulsants Phase 4
21 Dopamine Uptake Inhibitors Phase 4,Phase 2
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
23 Antidepressive Agents, Second-Generation Phase 4,Phase 2
24 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
25 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
27 Dopamine Agents Phase 4,Phase 2
28 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
29 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
30 Nicotinic Agonists Phase 4,Not Applicable
31
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
32
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
33
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
34
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
35
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 441203 84093 2767
36
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
37
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
38
Ethanol Approved Phase 3 64-17-5 702
39
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
40
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3,Not Applicable 437-38-7 3345
42
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
43
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 205923-56-4 56842117 2333
44
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
45
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
46
Cefazolin Approved Phase 3 25953-19-9 656510 33255
47
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
48
Sargramostim Approved, Investigational Phase 3,Phase 2,Not Applicable 123774-72-1, 83869-56-1
49
Histamine Approved, Investigational Phase 3,Not Applicable 51-45-6 774
50
Doxepin Approved, Investigational Phase 3,Not Applicable 1668-19-5 667468 667477

Interventional clinical trials:

(show top 50) (show all 419)
# Name Status NCT ID Phase Drugs
1 Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal Completed NCT03461328 Phase 4 Magnesium Sulphate
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Recruiting NCT03388931 Phase 4
5 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
6 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
7 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
8 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
9 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
10 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx Completed NCT00002496 Phase 3 chemotherapy;cisplatin;fluorouracil
11 Randomized Trial of ARCON in Larynx Cancer Completed NCT00147732 Phase 3
12 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
13 Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx Completed NCT00002839 Phase 3 cisplatin;fluorouracil
14 Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients Completed NCT00467948 Phase 3 cefazolin
15 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
16 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
17 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
18 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
19 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
20 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
21 Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord Completed NCT00002727 Phase 3
22 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
25 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
26 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
27 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
28 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
29 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
30 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
31 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
32 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
33 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
34 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
35 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
36 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
37 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
38 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
39 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
40 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
41 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
42 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
43 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
44 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
45 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
46 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
47 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
48 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
49 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
50 Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Sources

Genetic Tests for Larynx Cancer

About this section

Genetic tests related to Larynx Cancer:

# Genetic test Affiliating Genes
1 Laryngeal Carcinoma 30
Sources

Anatomical Context for Larynx Cancer

About this section

MalaCards organs/tissues related to Larynx Cancer:

42
Lung, Skin, Lymph Node, Breast, Brain, Liver, Endothelial
Sources

Publications for Larynx Cancer

About this section

Articles related to Larynx Cancer:

(show top 50) (show all 1242)
# Title Authors Year
1
Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease. ( 30681216 )
2019
2
Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. ( 30884136 )
2019
3
Improving decision making in larynx cancer by developing a decision aid: A mixed methods approach. ( 30663068 )
2019
4
Volumetric modulated arc therapy with robust optimization for larynx cancer. ( 30824150 )
2019
5
Phase I fractional dose escalation study of equipotent stereotactic radiotherapy regimens for early-stage glottic larynx cancer. ( 30880269 )
2019
6
Presentation of second primary cancers in young laryngeal carcinoma patients. ( 30712430 )
2019
7
Radiotherapy in advanced glottic laryngeal carcinoma in a patient with Wegener's granulomatosis: how much radiation dose is needed? ( 30774363 )
2019
8
Clinical Utility of Pretreatment and 3-Month 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive Radiation. ( 30808209 )
2019
9
β-Arrestin-1 expression and epithelial-to-mesenchymal transition in laryngeal carcinoma. ( 30854928 )
2019
10
The prognostic value of preoperative derived neutrophil-to-lymphocyte ratio in patients undergoing total laryngectomy with laryngeal carcinoma. ( 30882257 )
2019
11
Aspernolide A Inhibits the Proliferation of Human Laryngeal Carcinoma Cells through the Mitochondrial Apoptotic and STAT3 Signaling Pathways. ( 30893785 )
2019
12
Survival analysis of distant metastasis of laryngeal carcinoma: analysis based on SEER database. ( 30542764 )
2019
13
Tumor budding in laryngeal carcinoma. ( 30706852 )
2019
14
Quality of life in patients with larynx cancer in Latin America: Comparison between laryngectomy and organ preservation protocols. ( 29554402 )
2018
15
Epidemiological features of cancers of the oral cavity, oropharynx, hypopharynx and larynx cancer in RAcunion Island. ( 29673737 )
2018
16
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. ( 29598944 )
2018
17
Laryngeal Tuberculosis Mimicking Laryngeal Carcinoma on <sup>18</sup>F-FDG PET/CT Imaging. ( 29889030 )
2018
18
Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer. ( 29611770 )
2018
19
Comparative p16IKN4A Expression in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis. ( 30275203 )
2018
20
Does Socioeconomic Status Affect Stage at Presentation for Larynx Cancer in Canada's Universal Health Care System? ( 30200820 )
2018
21
Decision making in advanced larynx cancer: An evidenced based review. ( 30409301 )
2018
22
From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. ( 30409302 )
2018
23
Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies. ( 30409316 )
2018
24
Association of Hospital Volume With Laryngectomy Outcomes in Patients With Larynx Cancer. ( 30476965 )
2018
25
Comet assay is not useful to predict normal tissue response after radiochemotherapy in cervical and larynx cancer patients. ( 30786692 )
2018
26
Lemierre Syndrome as a Complication of Laryngeal Carcinoma. ( 29849275 )
2018
27
EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma. ( 28795320 )
2018
28
Does CT help in predicting preepiglottic space invasion in laryngeal carcinoma? ( 28807527 )
2018
29
Prognostic significance of soft tissue deposits in laryngeal carcinoma. ( 28823696 )
2018
30
The incidence of thyroid cartilage invasion in early-stage laryngeal carcinoma: Our experience on sixty-two patients. ( 28994198 )
2018
31
Transoral laser surgery for laryngeal carcinoma: has Steiner achieved a genuine paradigm shift in oncological surgery? ( 29046085 )
2018
32
Altered O-glycosylation is associated with inherent radioresistance and malignancy of human laryngeal carcinoma. ( 29179977 )
2018
33
Beclin1 enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2. ( 29322787 )
2018
34
Feasibility of Salvage Selective Neck Dissection after Primary Irradiation of Pharyngeal and Laryngeal Carcinoma. ( 29428959 )
2018
35
NBS1 rs2735383 polymorphism is associated with an increased risk of laryngeal carcinoma. ( 29433451 )
2018
36
Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells. ( 29503530 )
2018
37
Variation in prognosis of early laryngeal carcinoma after different types of cordectomy with transoral laser microsurgery. ( 29504443 )
2018
38
TIMP-3 Increases the Chemosensitivity of Laryngeal Carcinoma to Cisplatin via Facilitating Mitochondria-Dependent Apoptosis. ( 29523219 )
2018
39
The value of whole-body contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of patients with laryngeal carcinoma. ( 29533345 )
2018
40
MiR-632 promotes laryngeal carcinoma cell proliferation, migration and invasion through negative regulation of GSK3β. ( 29562960 )
2018
41
Laryngeal carcinoma in a father and son. Possible familial risk? ( 29619497 )
2018
42
Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway. ( 29687850 )
2018
43
High PINCH1 Expression in Human Laryngeal Carcinoma Associates with Poor Prognosis. ( 29755929 )
2018
44
Solitary femoral metastasis in a locoregionally controlled laryngeal carcinoma. ( 29761605 )
2018
45
Alterations in oxidative stress markers in laryngeal carcinoma patients. ( 29778552 )
2018
46
Oncological and functional outcomes of transoral laser surgery for laryngeal carcinoma. ( 29869708 )
2018
47
Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells. ( 29928333 )
2018
48
Nuclear nonmetastatic protein 23-H1 expression and epithelial-mesenchymal transition in laryngeal carcinoma: A pilot investigation. ( 29953715 )
2018
49
Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance. ( 29971915 )
2018
50
Effects of Different Treatment Strategies and Tumor Stage on Survival of Patients with Advanced Laryngeal Carcinoma: A 15-Year Cohort Study. ( 29973955 )
2018
Sources

Variations for Larynx Cancer

About this section

Cosmic variations for Larynx Cancer:

9 (show top 50) (show all 322)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6927812 ZFHX3 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.4946C>T p.S1649F 16:72797736-72797736 0
2 COSM45571 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.593A>G p.E198G 17:7674938-7674938 0
3 COSM10662 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
4 COSM10810 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.725G>T p.C242F 17:7674238-7674238 0
5 COSM4387403 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.680C>A p.S227Y 17:7674283-7674283 0
6 COSM11517 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.377A>G p.Y126C 17:7675235-7675235 0
7 COSM10660 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
8 COSM10654 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 0
9 COSM45685 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.613T>A p.Y205N 17:7674918-7674918 0
10 COSM10714 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.473G>T p.R158L 17:7675139-7675139 0
11 COSM11066 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>T p.H193L 17:7674953-7674953 0
12 COSM10905 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 0
13 COSM43690 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.592G>A p.E198K 17:7674939-7674939 0
14 COSM10779 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>T p.R273L 17:7673802-7673802 0
15 COSM10888 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.378C>A p.Y126* 17:7675234-7675234 0
16 COSM6549 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>T p.R248L 17:7674220-7674220 0
17 COSM12559 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.673-2A>T p.? 17:7674292-7674292 0
18 COSM43846 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.487T>C p.Y163H 17:7675125-7675125 0
19 COSM10659 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
20 COSM10893 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 0
21 COSM44475 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.871A>T p.K291* 17:7673749-7673749 0
22 COSM10813 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.394A>G p.K132E 17:7675218-7675218 0
23 COSM11462 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.388C>G p.L130V 17:7675224-7675224 0
24 COSM44219 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.405C>G p.C135W 17:7675207-7675207 0
25 COSM6906 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.672+1G>A p.? 17:7674858-7674858 0
26 COSM44067 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.721T>A p.S241T 17:7674242-7674242 0
27 COSM11658 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>T p.K319* 17:7673573-7673573 0
28 COSM11305 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.809T>C p.F270S 17:7673811-7673811 0
29 COSM44352 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.850A>C p.T284P 17:7673770-7673770 0
30 COSM44071 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>G p.K319E 17:7673573-7673573 0
31 COSM43583 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.425C>T p.P142L 17:7675187-7675187 0
32 COSM10889 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 0
33 COSM10758 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
34 COSM10742 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>G p.H193R 17:7674953-7674953 0
35 COSM10777 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.715A>G p.N239D 17:7674248-7674248 0
36 COSM44456 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.668C>A p.P223H 17:7674863-7674863 0
37 COSM11166 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 17:7675206-7675206 0
38 COSM43949 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.401T>G p.F134C 17:7675211-7675211 0
39 COSM10645 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 0
40 COSM44103 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.737T>A p.M246K 17:7674226-7674226 0
41 COSM43935 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.577C>A p.H193N 17:7674954-7674954 0
42 COSM44143 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.919+1G>A p.? 17:7673700-7673700 0
43 COSM10648 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
44 COSM44278 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.791T>C p.L264P 17:7673829-7673829 0
45 COSM43826 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.706T>A p.Y236N 17:7674257-7674257 0
46 COSM98254 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.782+1G>A p.? 17:7674180-7674180 0
47 COSM11374 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.752T>A p.I251N 17:7674211-7674211 0
48 COSM44678 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.415A>T p.K139* 17:7675197-7675197 0
49 COSM43947 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 0
50 COSM45544 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.947C>T p.P316L 17:7673581-7673581 0
Sources

Expression for Larynx Cancer

About this section
Search GEO for disease gene expression data for Larynx Cancer.
Sources

Pathways for Larynx Cancer

About this section

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 38
Show member pathways
 12.79 CCND1 CDKN2A EGFR GSTP1 TP53
2
Drug metabolism - cytochrome P450 38
Show member pathways
 12.73 GSTM1 GSTM3 GSTP1 GSTT1 NAT2 NME1
3
Glioma 38
Show member pathways
 12.6 CCND1 CDKN2A EGFR MMP2 TP53
4
Gastric cancer 38
Show member pathways
 12.48 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
5
DNA Damage 4
12.41 CCND1 CDKN2A GSTP1 TP53 XRCC1
6
MicroRNAs in cancer 38
12.39 CCND1 CD44 CDKN2A EGFR MIR21 SERPINB5
7
DNA Damage Response 1
Show member pathways
 12.29 CCND1 CDKN2A SERPINB5 TP53
8
Human T-cell leukemia virus 1 infection 38
12.28 CCND1 CDKN2A TERT TP53
9
Glutathione metabolism 23 38 1
Show member pathways
 12.21 GSTM1 GSTM3 GSTP1 GSTT1
10
Proteoglycans in cancer 38
12.21 CCND1 CD44 EGFR MIR21 MMP2 TP53
11
Colorectal Cancer Metastasis 65
12.09 CCND1 EGFR MMP2 TP53
12
Pathways in cancer 38
12.05 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
13
Direct p53 effectors 1
11.98 CTSD EGFR MMP2 SERPINB5 TP53
14
Fluid shear stress and atherosclerosis 38
11.94 GSTM1 GSTM3 GSTP1 GSTT1 MMP2 TP53
15
Senescence and Autophagy in Cancer 1
11.86 CD44 CDKN2A TP53
16
Glioblastoma Multiforme 65
11.84 CCND1 CDKN2A EGFR TP53
17
Angiogenesis (CST) 4
11.77 ENG MMP2 SERPINB5
18
Validated targets of C-MYC transcriptional activation 1
11.72 NME1 TERT TP53
19
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 62
Show member pathways
 11.7 GSTM1 GSTP1 GSTT1
20
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.7 CCND1 MMP2 TERT
21
Bladder cancer 38 1
11.67 CCND1 CDKN2A EGFR MMP2 TP53
22
Regulation of Telomerase 1
11.6 CCND1 EGFR TERT
23
Cell adhesion_ECM remodeling 23
11.55 CD44 EGFR MMP2
24
ATF-2 transcription factor network 1
11.5 CCND1 MMP2 SERPINB5
25
Hepatitis C and Hepatocellular Carcinoma 1
11.46 CCND1 CD44 TP53
26
Busulfan Pathway, Pharmacodynamics 62
Show member pathways
 11.38 GSTM1 GSTP1 NAT2
27
Photodynamic therapy-induced AP-1 survival signaling. 1
11.36 CCND1 CDKN2A EGFR MMP2 TP53
28
Platinum drug resistance 38
11.3 CDKN2A GSTM1 GSTM3 GSTP1 GSTT1 TP53
29
FOXM1 transcription factor network 1
11.29 CCND1 MMP2 XRCC1
30
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 62
11.15 GSTM1 GSTP1 GSTT1
31
Naphthalene metabolism 23
11.03 GSTM1 GSTP1 GSTT1
32
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 62
10.83 GSTP1 GSTT1
Sources

GO Terms for Larynx Cancer

About this section

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.85 ENG MIR21 NME1 TERT
2 negative regulation of apoptotic process GO:0043066 9.85 CD44 EGFR GSTP1 MIR21 TERT TP53
3 positive regulation of protein phosphorylation GO:0001934 9.76 CCND1 EGFR ENG MIR21
4 cellular response to drug GO:0035690 9.7 EGFR NME1 TP53
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.61 MIR21 MMP2 TERT
6 positive regulation of superoxide anion generation GO:0032930 9.56 EGFR GSTP1
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 EGFR TP53
8 mitotic G1 DNA damage checkpoint GO:0031571 9.51 CCND1 TP53
9 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.49 ENG MIR21
10 xenobiotic catabolic process GO:0042178 9.48 GSTM1 GSTM3
11 nitrobenzene metabolic process GO:0018916 9.4 GSTM1 GSTM3
12 replicative senescence GO:0090399 9.33 CDKN2A TERT TP53
13 cellular detoxification of nitrogen compound GO:0070458 9.32 GSTM1 GSTM3
14 response to UV-A GO:0070141 9.26 CCND1 EGFR
15 glutathione metabolic process GO:0006749 9.26 GSTM1 GSTM3 GSTP1 GSTT1
16 glutathione derivative biosynthetic process GO:1901687 8.92 GSTM1 GSTM3 GSTP1 GSTT1

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.65 CCND1 CDKN2A EGFR GSTP1 TP53
2 enzyme binding GO:0019899 9.5 CCND1 EGFR GSTM1 GSTM3 NME1 TP53
3 glutathione binding GO:0043295 9.33 GSTM1 GSTM3 GSTP1
4 glutathione transferase activity GO:0004364 8.92 GSTM1 GSTM3 GSTP1 GSTT1
Sources

Sources for Larynx Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....